Eli Lilly, the American pharmaceutical giant, has made two significant announcements that could substantially impact its market position and future growth tr ...
Walmart is joining Costco, Sam’s Club, and CVS in offering cheaper prices for customers paying out of pocket for Zepbound, ...
After Pfizer agreed to acquire weight-loss drug developer Metsera for $7.3 billion, Novo Nordisk swooped in with an ...
DES MOINES, Iowa, Nov. 4, 2025/PRNewswire/ -- BioSpace, the leader in biopharma news and careers, has published its 2026 Best Places to Work list.
Aion Medicines, a subsidiary of Exavir Therapeutics, announced the presentation of preclinical data for AM-710, the company's ultra-long-acting small molecule GLP1R agonist, at the ObesityWeek ...
US pharma major Eli Lilly has revealed plans to build a new $3 billion manufacturing facility in Katwijk, the Netherlands, ...
Indianapolis-based Eli Lilly and Company announced Monday, Nov. 3 that it plans to build a new $3 billion manufacturing ...
American pharmaceutical company Eli Lilly plans to build a $3bn manufacturing facility at the Leiden Bio Science Park in ...
PCSK9 inhibition may be a suitable alternative for statin-intolerant patients, and recent data demonstrated its efficacy as ...
The hyperlipidemia drugs market is growing due to rising cardiovascular disease prevalence, increasing cholesterol management ...
Weight loss drugs are set to become a disproportionate share of Lilly's business.
Zacks Investment Research on MSN
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback